Publications by authors named "Kezhuo Shang"
Background: Liver cancer is largely resistant to chemotherapy. This study aimed to identify the effective chemotherapeutics for β-catenin-activated liver cancer which is caused by gain-of-function mutation of catenin beta 1 ( CTNNB1 ), the most frequently altered proto-oncogene in hepatic neoplasms.
Methods: Constitutive β-catenin-activated mouse embryonic fibroblasts (MEFs) were established by deleting exon 3 ( β-catenin Δ(ex3)/+ ), the most common mutation site in CTNNB1 gene.
Background: Although β-catenin signaling cascade is frequently altered in human cancers, targeting this pathway has not been approved for cancer treatment.
Methods: High-throughput screening of an FDA-approved drug library was conducted to identify therapeutics that selectively inhibited the cells with activated β-catenin. Efficacy of iron chelator and mitochondrial inhibitor was evaluated for suppression of cell proliferation and tumorigenesis.
, encoding β-catenin protein, is the most frequently altered proto-oncogene in hepatic neoplasms. In this study, we studied the significance and pathological mechanism of gain-of-function mutations in hepatocarcinogenesis. Activated β-catenin not only triggered hepatic tumorigenesis but also exacerbated deletion or hepatitis B virus infection-mediated liver cancer development in mouse models.
View Article and Find Full Text PDFOverexpressed PKM2 promotes macrophage phagocytosis and atherosclerosis.
Animal Model Exp Med
April 2023
Background: The expression of pyruvate kinase muscle 2 (PKM2) is augmented in macrophages of patients with atherosclerotic coronary artery disease. The role of PKM2 in atherosclerosis is to be determined.
Methods: Global and myeloid cell-specific PKM2 knock-in mice with ApoE background (ApoE , PKM2 and Lyz2-cre, ApoE , and PKM2 ) were produced to evaluate the clinical significance of PKM2 in atherosclerosis development.